Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.48 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.48 |
| ▸ | ULK1 | O75385 | 1/20 | 0.48 |
| ▸ | IGF1R | P08069 | 8/20 | 0.47 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11917265 | 0.89 | NEK1 (0.47) | NEK1CCNA2CDK2CCNA1ULK1 | |
| SCHEMBL11917254 | 0.88 | IGF1R (0.48) | IGF1R | |
| SCHEMBL11917257 | 0.86 | AURKA (0.48) | CCNA2CDK2CCNA1SRCGSK3B | |
| SCHEMBL802688 | 0.81 | IGF1R (0.63) | NEK1CCNA2CDK2CCNA1ULK1 | |
| SCHEMBL11917244 | 0.80 | IGF1R (0.46) | CDK2IGF1R | |
| SCHEMBL17525309 | 0.80 | NEK1 (0.67) | NEK1IGF1RSRCGSK3B | |
| SCHEMBL16246886 | 0.78 | IGF1R (0.61) | IGF1R | |
| SCHEMBL11916921 | 0.78 | AURKA (0.49) | NEK1CCNA2CDK2CCNA1IGF1R | |
| SCHEMBL11917243 | 0.77 | IGF1R (0.48) | NEK1CCNA2CDK2CCNA1IGF1R | |
| SCHEMBL17525325 | 0.77 | NEK1 (0.82) | NEK1IGF1RSRCGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202818-A1 | UREIDOPHENYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202818-A1 | UREIDOPHENYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | UCK2, ULK2, ULK1 | NEK1 96/4885CCNA2 1145/4885CDK2 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.